At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 12, 2026 at 07:00 ET
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $30.4M a year ago due to increased R&D spending on late-stage trials. The stock is driven by upcoming catalysts: top-line Phase 3 OPERA-01 data expected fall 2026 and initial Phase 1 OP-3136 data at ASCO this month.
- Q1 2026 EPS -$0.52 vs consensus -$0.54 (7.2% beat)
- Net loss $53.1M vs $30.4M YoY, driven by higher R&D spend
- Cash position $505.3M as of March 31, 2026
- Top-line Phase 3 OPERA-01 data expected fall 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access